Protein kinase C isoforms: Mediators of reactive lipid metabolites in the development of insulin resistance  by Turban, Sophie & Hajduch, Eric
FEBS Letters 585 (2011) 269–274journal homepage: www.FEBSLetters .orgReview
Protein kinase C isoforms: Mediators of reactive lipid metabolites
in the development of insulin resistance
Sophie Turban d, Eric Hajduch a,b,c,⇑
aCentre de Recherche des Cordeliers, INSERM, U872, Paris F-75006, France
bUniversité Pierre et Marie Curie, Paris VI, UMR S872, Paris F-75006, France
cUniversité Paris Descartes, UMR S872, Paris F-75006, France
dMolecular Metabolism Group, Centre for Cardiovascular Science, The Queen’s Medical Research Institute, University of Edinburgh, Edinburgh EH16 4TJ, United Kingdom
a r t i c l e i n f o a b s t r a c tArticle history:
Received 12 November 2010
Revised 7 December 2010
Accepted 14 December 2010
Available online 19 December 2010
Edited by Robert Barouki
Keywords:
Insulin
Ceramide
DAG
Protein kinase B
Akt
Obesity0014-5793/$36.00  2010 Federation of European Bio
doi:10.1016/j.febslet.2010.12.022
⇑ Corresponding author at: Centre de Recherche d
Paris F-75006, France. Fax: +33 1 40 51 85 86.
E-mail address: eric.hajduch@crc.jussieu.fr (E. HajdThe role of protein kinase C (PKCs) isoforms in the regulation of glucose metabolism by insulin is
complex, partly due to the large PKC family consisting of three sub-groups: conventional, novel
and atypical. Activation of some conventional and novel PKCs in response to increased levels of diac-
ylglycerol (DAG) have been shown to counteract insulin signalling. However, roles of atypical PKCs
(aPKCs) remain poorly understood. aPKCs act as molecular switches by promoting or suppressing
signalling pathways, in response to insulin or ceramides respectively. Understanding how DAG-
and ceramide-activated PKCs impair insulin signalling would help to develop treatments to ﬁght
insulin resistance.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Insulin is a hormone essential for growth, energy storage and
maintenance of glucose homeostasis. Defects in its secretion and
action are critical for the development of metabolic diseases such
as diabetes, obesity, hypertension, atherosclerosis and cardiovas-
cular disease [1]. It is known for some time now that elevated cir-
culating free fatty acid (FFA) levels observed during obesity are
involved in the development of insulin resistance in peripheral tis-
sues such as white adipose tissue, skeletal muscle, liver, pancreas
and heart [2]. In fact, forcing non-adipose cells to store fatty acids
beyond their capacities promotes insulin resistance by inducing
ectopic fat deposition [2]. First, and like in adipocytes, cells are pro-
tected from the deleterious effects of lipids by storing them as tri-
glycerides in small lipid droplets [3]. However, quickly, and in
opposite to what is observed in adipocytes, the storage capacity
of non-adipose cells is limited, and overload generates lipotoxicity
by promoting accumulation of intracellular signalling molecules
that are able to inhibit insulin action [4]. Among these fatty acid-
derived lipids, diacylglycerol (DAG) and ceramides are the most ac-chemical Societies. Published by E
es Cordeliers, INSERM, U872,
uch).tive to negatively regulate intermediates of the insulin signalling
pathway, and consequently to inhibit glucose metabolism [5].
Interestingly, down-regulation of insulin signalling by both DAG
and ceramides is mediated through concomitant activation of
members of the protein kinase C (PKC) family of serine/threonine
kinases. This review summarises the ongoing progress about the
involvement of these kinases in the development of insulin resis-
tance in insulin-sensitive tissues.
2. PKC family
PKCs belong to the AGC (cAMP-dependent protein kinase/PKG/
PKC) protein kinases family that play important roles in many
intracellular signalling events, cell growth and differentiation [6].
The PKC family consists of three different groups: conventional
(a, b1, b2 and c), novel (d, e, g and h), and atypical (f and k/s)
(Fig. 1). Conventional and novel PKC isoforms are lipid-sensitive
enzymes and are usually activated by growth factors through stim-
ulation of phospholipase C (PLC) which hydrolyzes phosphatidylin-
ositol-4,5-bisphosphate (PIP2) to generate DAG and inositol
triphosphate (IP3). On the other end, atypical PKC (aPKC) are
mainly activated by protein–protein interactions and phosphoryla-
tions by 3-phosphoinositide-dependent protein kinase 1 (PDK1).
Conventional PKC (cPKC) isoforms contain two regulatory domainslsevier B.V. All rights reserved.
Fig. 1. Structure of PKC isoforms. PKC isoforms are divided into three different groups that contain conserved regions (C1–C4). cPKCs are activated by Ca2+ which binds to the
C2 region, and by DAG and phorbol esters that bind to the C1 region. nPKCs lack the Ca2+ binding site in their C2 region and are solely activated by DAG and phorbol esters
through binding to the C1 region. aPKCs, however, completely lack the C2 region and possess a modiﬁed C1 region for phosphatidylinositol-3,4,5-triphosphates (PIP3) and
ceramides binding. All PKCs possess an auto-inhibitory pseudosubstrate sequence (PS) which is attached to the catalytic domain, therefore blocking access of substrates in the
basal state of the kinase, until activators induce conformational changes and promote substrate accessibility. C3 and C4 are highly conserved regions which bind ATP and
protein substrates, respectively.
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phorbol esters such as phorbol 12-myristate 13-acetate (PMA),
while C2 domain binds anionic phospholipids in a calcium-depen-
dent manner (Fig. 1) [6]. Novel PKC (nPKC) isoforms possess a sim-
ilar C1 domain but lack calcium binding sites in their C2 domain,
meaning that they are activated by DAG and phorbol esters inde-
pendently of calcium (Fig. 1). aPKC isoforms contain a C1 domain
that binds phosphatidylinositol-3,4,5-triphosphates (PIP3) and
ceramides, but not DAG or phorbol esters and completely lack
the calcium-sensitive C2 domain (Fig. 1) [6].
More and more evidences in the literature highlight the
crucial role of key PKCs in regulating insulin signalling and espe-
cially their participation to mechanisms that induce insulin
resistance.
3. PKCs, important actors in the regulation of insulin action
3.1. Positive implication of PKCs in the insulin signalling pathway
In adipocytes and muscle cells insulin signal transduction is ini-
tiated by the activation of the insulin receptor, a tyrosine kinase
that phosphorylates intracellular substrates, in particular the fam-
ily of insulin receptor substrates (IRS 1–4 proteins) on several tyro-
sine residues [7,8]. Numerous proteins can dock on activated IRSs,
and among them phosphoinositide-3-kinase (PI3K) and down-
stream effectors such as serine/threonine kinases protein kinase
B (PKB, also known as Akt) and aPKC fk which play a crucial role
in glucose homeostasis [9,10]. This is the generation of phosphati-
dylinositol-3,4,5-triphosphate (PIP3) by PI3K that recruits both
aPKCs and PKB/Akt to the plasma membrane. Once recruited,
aPKCs are phosphorylated by PDK1 on their Thr410/403 sites [8].
Meanwhile, PIP3 binds to the pleckstrin homology (PH) domain
of PKB/Akt, inducing a conformational change in the kinase that
exposes two regulatory sites, Thr308 and Ser473 (for PKBa/Akt1).
Phosphorylation of Thr308 is then mediated by 3-phosphoinosi-
tide-dependent protein kinase 1 (PDK1) and Ser473 by mammalian
target of Rapamycin(mTOR)–Rapamycin-insensitive companion of
mTOR (Rictor) complex [8]. Activated PKB/Akt phosphorylates
the Rab-GAP AS160 protein on several sites [11], allowing signal
transmission via the activation of Rab proteins (Rab8A, 10 and
14) and the release of Glut4 vesicles to the plasma membrane
[11] (Fig. 2). Simultaneously, in skeletal muscle insulin-activated
PKB/Akt promotes glycogen synthesis after phosphorylation, andthus inhibition of glycogen synthase kinase 3 (GSK3) [9]. In liver
cells, insulin signalling pathway shares great similarities with the
one described in adipose or muscle cells, where insulin-activated
PKB/Akt promotes glycogen synthesis and inhibits gluconeogenesis
(Fig. 2) [5].
Direct implication of aPKCs in regulating Glut4 vesicles translo-
cation under insulin action in adipocytes and muscle cells was
shown by overexpressing dominant negative mutants of both PKCf
and PKCk [12]. Moreover, by using a slightly different approach
with PKCf inhibitors and PKCf-siRNA, PKCf has been shown to be
involved in the stimulatory effect of insulin on PKB/Akt and subse-
quent GLUT4 translocation through its interaction with actin cyto-
skeleton by inducing actin remodelling in L6 muscle cells [13]. This
suggests that aPKCs not only participate to insulin signalling cas-
cade but also to insulin-stimulated GLUT4 vesicle trafﬁcking. How-
ever, the involvement of aPKCs in the insulin-dependent regulation
of glucose transport was recently questioned. A study using PKCk-
depleted L6 muscle cells demonstrated that PKCk is likely to be dis-
pensable with respect to insulin-stimulated glucose uptake [14].
Indeed PKCk-depleted muscle cells were more sensitive to insulin
than wild-type control cells, suggesting that instead of mediating
insulin signalling actions, PKCk was more likely to restrain them
[14]. Those data are in discordance with recent report on the role
of PKCk in vivo in a transgenic mice model lacking PKCk in their
skeletal muscle cells. These mice developed insulin resistance,
presented reduced glucose tolerance and dyslipidemia, all common
features of the metabolic syndrome [15]. Although those data con-
tribute to the understanding of the effect of aPKCs activation in
insulin signalling, a complete dissection of the mechanisms by
which aPKCs interact with other components of the signal remains
to be realised.
3.2. Other isoforms of PKCs in the insulin signalling pathway
Other cPKC and nPKC isoforms were also found to positively
modulate insulin signalling. Indeed, splicing of PKCb pre-mRNA
into PKCb2 by insulin for remodelling cytoskeleton seems neces-
sary to allow the relocation of GLUT4 vesicles at the plasma mem-
brane in response to insulin in muscle cells [16]. In addition PKCd
was also shown to activate insulin-stimulated glucose transport in
muscle cells by interacting and helping internalization of the insu-
lin receptor into internal membranes after stimulation by the
hormone.
Fig. 2. Insulin signalling pathway. Insulin activates the insulin receptor kinase, leading to the activation of IRSs, PI3-kinase and PKB/Akt. Activated PKB/Akt promotes GLUT4
translocation to the plasma membrane and glucose uptake in adipocytes and skeletal muscle, as well as glycogen synthesis in skeletal muscle and liver. In liver, insulin
promotes lipogenesis and inhibits gluconeogenesis.
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regulation of insulin signalling and looking at the literature, more
members of PKC family might be involved at different levels of
regulation.
4. Implication of PKCs as mediators of insulin resistance
Pan et al. were between the ﬁrst to demonstrate that intramus-
cular lipid accumulation was associated with insulin resistance
[17], followed by Boden et al. showing that infusing lipids intra-
muscularly to patients was also triggering insulin resistance [18].
Although these data indicated the existence of a relationship be-
tween lipid accumulation and reduced insulin signalling pathway,
metabolic events connecting fatty acid oversupply to insulin resis-
tance were still not resolved completely at that time. The time
frame by which insulin resistance developed (2–4 h after an acute
elevation in plasma free fatty acids) indicated an indirect effect of
fatty acids on insulin signalling [18], and indeed, an accumulation
of reactive lipid intermediates such as DAG and ceramides have
been observed in skeletal muscle of insulin-resistant animals
[19,20], as well as in human obese subjects with type 2 diabetes
[21]. Both lipid intermediates have been demonstrated to play
important roles in the establishment of insulin resistance in insu-
lin-sensitive tissues, and their negative action on the insulin sig-
nalling pathway is often mediated by several members of the
PKC family.
4.1. Diacylglycerol-activated PKCs
DAG, generated by breakdown of phospholipids or through de
novo synthesis via the esteriﬁcation of excess long-chain fatty
acyl-CoA into glycerol-3-phosphate, are precursors to triglycerides,
but are also thought to act as important second messengers in the
regulation of insulin signalling. Interestingly, several studies have
shown signiﬁcant increase in DAG content in skeletal muscle of
high-fat fed rats [22], insulin-resistant humans [23], diabetic GK
rats [24], as well as in liver of obese homozygous Lepdb/db mice
[25], and obese Zucker rats [26]. However, to our knowledge there
is little evidence for an elevation of DAG contents leading to insulin
resistance in adipocytes. Elevated levels of DAG in different tissues
lead to the activation of several PKC isoforms such as PKCa, PKCd,PKCh, PKCe and PKCb1 [27]. However, only few of them have been
consistently involved in the negative action of DAG on insulin sig-
nalling. In rodents or human muscle cells, elevated DAG contents
are mainly associated with an increased activation of both PKCh
and PKCe, and related to inhibition of insulin action in these cells
[27,28]. The involvement of PKCh in the development of insulin
resistance was conﬁrmed by using PKCh knockout mice. In these
mice, the lack of PKCh protected muscle cells against insulin resis-
tance induced by lipid infusion [29]. In liver, the speciﬁc role of
PKCe in mediating DAG harmful actions has been shown by using
PKCe antisense oligonucleotides in rats fed with a high fat diet.
These rats accumulated DAG in the liver and knocking down PKCe
expression speciﬁcally in this tissue prevented rats from fat-in-
duced hepatic insulin resistance [27]. PKCe has also been shown
to be activated in liver of patients with type 2 diabetes [30] and
high-fat fed rats [31] suggesting once again its participation in
the development of insulin resistant obesity.
Cellular mechanisms by which DAG-activated PKC isoforms
down-regulate insulin signalling are better understood. It appears
that DAG-activated PKCs target IRS proteins, one of the ﬁrst events
in the insulin signalling pathway (Fig. 3A). Indeed inactivation of
IRSs is mediated by phosphorylation on one or several of its 200
serine/threonine residues. On the one hand, PKCh can act upstream
of the stress kinases IjBa kinaseb (IKKb) and c-Jun NH2-terminal
kinase (JNK) to phosphorylate IRS-1 on serine residues Ser301
[27], Ser302 and Ser307 [32], but PKCh can also phosphorylate
IRS-1 directly on its serine residue Ser1101 [33] and Ser307 [22].
On the other hand, DAG-activated PKCe inhibits IRS-1 by increas-
ing its phosphorylation on Ser636/639 residues [34] (Fig. 3A). In
addition, PKCe associates directly with the insulin receptor and
thus impairs its kinase activity [35]. More convincing evidences
on the implication of IRS serine phosphorylation in the develop-
ment of insulin resistance was pointed out in mice in which resi-
dues Ser302, Ser307, and Ser612 of IRS-1 were mutated to
alanine [36]. These mice were partially but signiﬁcantly protected
against fat-induced insulin resistance [36]. However, it seems that
the phosphorylation of serine 307 of IRS-1 might be insufﬁcient to
impair insulin signalling in skeletal muscle. Surprisingly, knock-in
mice in which the serine 307 residue was replaced by an alanine
(A/A) residue developed a more profound resistance to insulin
compare to their wild-type littermates under diet-induced obesity
Fig. 3. Implication of PKC isoforms in the development of fatty-acid induced insulin resistance. Insulin resistance result from excess accumulation of fatty acids in ectopic
tissues, leading to production of lipid metabolites like DAG and ceramides. (A) High levels of DAG in insulin-sensitive tissues impair insulin signalling at the level of IRSs. DAG
is thought to act through both conventional and novel PKCs that induce the phosphorylation of IRSs on serine residues, thus reducing signalling to downstream effectors. (B)
Increased levels of ceramides inhibit insulin signalling in insulin sensitive cells through the association between ceramide-activated PKCf and PKB/Akt. PKCf-bound PKB/Akt
is phosphorylated by PKCf on its Thr34 residue, therefore preventing PKB/Akt to bind PIP3 and to be recruited to the plasma membrane where it is activated by insulin.
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alone is a positive regulatory site for insulin sensitivity and that
more than one serine residue have to be phosphorylated in re-
sponse to elevated DAG to induce insulin resistance.
The speciﬁc implication of the DAG-PKC pathway in the devel-
opment of insulin resistance in skeletal muscle has been conﬁrmed
recently by artiﬁcially increasing DAG contents in muscle cells
[24]. Chibalin et al. [24] showed that the inhibition of DGKd (diac-
ylglycerol kinase d), enzyme phosphorylating DAG to produce
phosphatidic acid in vitro in rat muscle strips, induced an elevation
of DAG contents which is followed by the activation of novel/con-
ventional PKCs and increased phosphorylation of IRS-1 on both
Ser307 and Ser302 residues. Serine phosphorylation of IRS-1 pre-
vented insulin to induce IRS-1 tyrosine phosphorylation, PI3-ki-
nase activity and PKB/Akt phosphorylation, leading to an
inhibition of insulin-induced glucose uptake in these cells [24].
Moreover, this study showed that both the expression and the
activity of DGKdwere reduced in skeletal muscle of type 2 diabetic
patients, as well as in diabetic animals [24]. Thus, this important
ﬁnding further emphasises the role of DAG and PKCs as importantmediators in the regulation of hyperglycaemia-induced impair-
ment of peripheral insulin sensitivity.
4.2. aPKCs mediate ceramide action
Ceramides are derivatives of sphingomyelin and are generated
either by sphingomyelinase, via de novo synthesis using palmitate
as a precursor, or by the salvage pathway that uses sphingosine
through reacylation to produce ceramides [38]. Ceramides are rel-
atively minor components of cell membranes but are known to be
mediators of very important cellular processes such as apoptosis,
proliferation and differentiation [5]. Like DAG, ceramides accumu-
late in skeletal muscle of insulin-resistant animals [19,39], lipid in-
fused humans [40], and in type 2 diabetic patients [21]. Several
in vivo and in vitro studies have demonstrated that accumulation
of ceramides inhibited insulin signalling [5]. Reciprocally, artiﬁ-
cially blocking de novo ceramide biosynthesis by pharmacological
inhibition of serine palmitoyl transferase (SPT), ﬁrst enzyme in the
ceramide biosynthesis pathway, prevented the onset of insulin
resistance in cells and in animals [5].
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ceramides. Indeed, defects in activation of this kinase induced by
ceramides have been observed in several cell types, such as white
and brown adipocytes, skeletal and smooth muscles, mammary
cells and nerve cells [5]. In some cells, ceramides acts on PKB/Akt
through the direct activation of phosphatases such as the protein
phosphatase-2A (PP2A) [5], a cytosolic serine/threonine phospha-
tase responsible for dephosphorylating PKB/Akt. Treatment of
C2C12 muscle cells, PC12 nerve cells and brown adipocytes with
the PP2A inhibitor okadaic acid (OKA) [41] prevented negative ef-
fects of ceramides on PKB/Akt [5]. However, in L6 muscle cells and
white adipose tissue, we and others have shown that ceramides
inhibited insulin-stimulated glucose transport through a mecha-
nism that does not involve a phosphatase [42,43]. Ceramides have
been shown for a long time to activate aPKCs [44], and recently, a
speciﬁc protein fragment of PKCf has been demonstrated to bind
ceramides [45]. We demonstrated that ceramide-activated PKCf
interacted and phosphorylated the PH domain of PKB/Akt on a
Thr34/Ser34 residue (Thr34 in PKBa/Akt1 and PKBb/Akt2, and
Ser34 in PKBc/Akt3), thus preventing PKB/Akt to be recruited to
the plasma membrane where the kinase is normally activated in
response to insulin (Fig. 3B) [39,44]. Inhibition of PKB/Akt activity
after phosphorylation of its Thr34/Ser34 residue by PKCf in re-
sponse to ceramides has been conﬁrmed by Fox et al. in rat aorta
vascular smooth muscle cells (A7r5) [46]. They overexpressed a
mutated PKBc/Akt3 construct in which the Ser34 residue was re-
placed by a glutamate to mimic phosphorylation. This mutant
reproduced the ceramide repressive action on PDGF- stimulated
PKBc/Akt3 activity. Inversely replacement of Ser34 residue by an
alanine to prevent PKCf phosphorylation completely impaired cer-
amide inhibition of PKBc/Akt3 [46]. Altogether, these results dem-
onstrated the importance of PKCf in mediating ceramide-induced
insulin resistance (Fig. 3B).
Recently, we and others have shown that ceramides induced the
recruitment of both PKCf and PKB/Akt in specialized domains of
the plasma membrane called caveolin-enriched microdomains
(CEM) [46,47]. These microdomains also called lipid rafts are be-
lieved to form platforms for conducting a variety of cellular func-
tions [48]. Most of cellular ceramides are concentrated in these
domains, typically enriched with cholesterol, sphingolipides and
caveolins [46]. Caveolins are the major coat constituent of a class
of sub-microdomains present in these CEM, called caveolae. In
addition to their structural role, caveolins can segregate signal ini-
tiation events by concentrating and organizing signalling mole-
cules through their speciﬁc caveolin scaffolding domain [47].
Interestingly, caveolins were shown to interact with PKCf via their
scaffolding domain, explaining why this kinase is well represented
in caveolae [49]. Because these caveolae are particularly abundant
in adipocytes, endothelial cells and muscle cells [50], we hypothe-
sised that ceramides could repress insulin signalling through seg-
regation of both PKB/PKCf in these sub-microdomains. We found
in adipocytes as well as in L6 muscle cells that elevated contents
of ceramides induce the recruitment of PKB/PKCf complex in
CEM where PKB/Akt is held in a repressed state, and unable to sup-
port the hormonal activation of glucose transport [47]. However, in
cells with low caveolin expression, in other words basically devoid
of these domains, the PKCf pathway is inactive and ceramides in-
hibit PKB/Akt mainly via PP2A [41]. Therefore the compartmental-
ization of the plasma membrane into sub-microdomains is a
crucial determinant for the pathway used by ceramides to inhibit
PKB/Akt [41].
These data highlight that redundant pathways exist within cells
to mediate negative actions of ceramides on insulin sensitivity.
This clearly indicates that targeting a single pathway (either PKCf
or PP2A) would not be efﬁcient strategies to ﬁght ceramide-in-
duced insulin resistance. Instead, ﬁnding a way to prevent cera-mide accumulation in insulin-sensitive tissues would be a better
approach as possible therapeutic intervention.
5. Conclusion and future direction
Recent studies have highlighted PKCs as a family of multifunc-
tional enzymes that play crucial roles in the transduction of many
cellular signals by phosphorylating various targets. In the speciﬁc
context of glucose metabolism, some are operating either as medi-
ators (PKCfk, b2, c) or inhibitors (PKCfk, a, d, h, e, b1) of the insulin
signal, depending on their activating stimuli. Regarding the con-
cerning picture of worldwide increasing incidence of insulin resis-
tant obesity, highlighting PKC isoforms as regulators of lipid-
induced insulin resistance have been a real breakthrough into the
understanding in the mechanisms leading to this disease. Indeed,
it has now become clear that PKCh in muscle, and PKCe in liver re-
lay DAG-induced insulin resistance in these tissues. Similarly,
implication of PKCfk in mediating the deleterious effects of cera-
mides in muscle cells and adipocytes has now been well
established.
However, most of the studies have been carried out in these tis-
sues, and future research should be extended to other tissues such
as pancreas and heart, also critical organs targeted during diabetes
and cardiovascular diseases. Therefore, understanding how DAG-
and ceramide-activated PKCs impair insulin signalling in ectopic
tissues will help to design new drugs to treat insulin resistance
and other obesity-linked disorders.
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